SCHEMBL21751110

SCHEMBL21751110

Nc1cccc(F)c1C(=O)NC1CCC(=O)NC1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 20/20 1.00
DDB1 Q16531 4/20 0.60
IKZF3 Q9UKT9 1/20 0.58
BRD4 O60885 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20811949 0.91 CRBN (0.83) CRBNDDB1IKZF3BRD4
SCHEMBL21769114 0.86 CRBN (0.76) CRBNDDB1IKZF3BRD4
SCHEMBL283113 0.85 CRBN (0.74) CRBNDDB1IKZF3BRD4
SCHEMBL282792 0.85 CRBN (0.74) CRBNDDB1IKZF3BRD4
SCHEMBL4778581 0.84 CRBN (0.73) CRBNDDB1IKZF3BRD4
SCHEMBL4781353 0.83 CRBN (0.77) CRBNDDB1IKZF3BRD4
SCHEMBL26646479 0.83 CRBN (0.77) CRBNDDB1IKZF3BRD4
SCHEMBL21751086 0.81 CRBN (0.69) CRBNDDB1IKZF3BRD4
SCHEMBL4780875 0.81 CRBN (0.68) CRBNDDB1IKZF3
SCHEMBL17169744 0.80 CRBN (1.00) CRBNDDB1IKZF3BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479840-B2 HMG-CoA reductase degradation inducing compound UPPTHERA INC. (KR) 2025-11-25 US disclosed
CN-115666575-B Compounds and uses thereof 福宏治疗公司 2024-12-10 CN disclosed
US-11807620-B2 Quinazolinone compounds and related compounds Plexium, Inc. (US) 2023-11-07 US disclosed
US-11807620-B2 Quinazolinone compounds and related compounds Plexium, Inc. (US) 2023-11-07 US disclosed
US-11807620-B2 Quinazolinone compounds and related compounds Plexium, Inc. (US) 2023-11-07 US disclosed
CN-110621664-B Novel piperidine-2, 6-dione derivatives and uses thereof 韩国化学研究院 2023-08-01 CN disclosed
US-20230150974-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230150974-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230078961-A1 HMG-CoA Reductase Degradation Inducing Compound UPPTHERA INC. (KR) 2023-03-16 US disclosed
EP-4132529-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2023-02-15 EP disclosed
CN-115666575-A Compound and use thereof 福宏治疗公司 2023-01-31 CN disclosed
EP-3623366-B9 NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF KOREA RES INST CHEMICAL TECH (KR) 2022-06-15 EP disclosed
EP-3623366-B1 NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF KOREA RES INST CHEMICAL TECH (KR) 2022-01-19 EP disclosed
US-11192878-B2 Piperidine-2,6-dione derivative and use thereof KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2021-12-07 US disclosed
US-11192878-B2 Piperidine-2,6-dione derivative and use thereof KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2021-12-07 US disclosed
WO-2021201577-A1 HMG-COA REDUCTASE DEGRADATION INDUCING COMPOUND UPPTHERA (KR) 2021-10-07 WO disclosed
EP-3623366-A1 NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF Korea Research Institute of Chemical Technology (KR) 2020-03-18 EP disclosed
US-20200062730-A1 NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF UBIX THERAPEUTICS, INC. (KR) 2020-02-27 US disclosed
US-20200062730-A1 NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF UBIX THERAPEUTICS, INC. (KR) 2020-02-27 US disclosed
CN-110621664-A Novel piperidine-2, 6-dione derivatives and uses thereof 韩国化学研究院 2019-12-27 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150974-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB CRBN 179/4885DDB1 987/4885IKZF3 1442/4885
US-20200062730-A1 NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF CRBN, PDCD11, CD47 CRBN 1/4885DDB1 153/4885IKZF3 969/4885
US-11192878-B2 Piperidine-2,6-dione derivative and use thereof CRBN, PDCD11, CD47 CRBN 1/4885DDB1 196/4885IKZF3 822/4885
US-11807620-B2 Quinazolinone compounds and related compounds NQO2, COQ8A, PARK7 CRBN 2403/4885DDB1 807/4885IKZF3 3552/4885
US-20230078961-A1 HMG-CoA Reductase Degradation Inducing Compound HMGCR, HMGB2, LDLR CRBN 1616/4885DDB1 798/4885IKZF3 2579/4885
US-12479840-B2 HMG-CoA reductase degradation inducing compound HMGCR, HMGB2, LDLR CRBN 1616/4885DDB1 798/4885IKZF3 2579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.